Partnership on preclinicals that are decades away and long shots for approval are supposed to move the pps now?
That is a significant modification to the original agreement and should have been disclosed by Sunil.
Read the 8K and tell us what the lie is?
You are squealing like a pig but not saying anything of substance to counter the latest Sunil give away.
Maybe that is why Titan has not been able to license the ROW.
Addiction is high in Russia, but they have a law against replacement therapy, that is, you can't prescribe an addictive drug to replace the drug that the patient is addicted to.
You'll know what in the next two weeks?
What will the royalty be if Probuphine is approved and competition enters the scene?
You don't know if Probuphine will be approved, but more important, how can you make a determination on the value of Titan without knowing what the royalty was reduced to?
The stock price is in the toilet, penny didn't get it there, Sunil did.
You are taking your frustration out on the wrong person.
There is no $165M. You have nothing approved and Sunil just reduced the already low potential royalties to a lower amount.
How is posting a section from the amended agreement and citing the source, spreading misinformation?
Isn't a message board a place to post information?
Aren't you shocked that Sunil did not disclose this modification in the PR?
What half truths are you referring to? Sunil's half truths?
There's a meeting scheduled with the FDA in December.
The FDA had 3 questions.
It was stated that the Company had answers to two of them and wanted clarification on the other.
I would expect a resubmission, if necessary in January and approval around mid year.
and he knows how to ream the baggies: $50 to 50 cents.
Aren't you tired of being wrong?
"The FDA has requested additional data supporting the efficacy of Probuphine, including:
The ability of Probuphine to provide opioid blockade of relevant doses of agonists
The effect of higher doses of Probuphine, ideally doses more closely approximating the blood plasma levels associated with sublingual doses of buprenorphine of 12 to 16 mg / day"
How do you get the data requested by the FDA without additional trials?
Try: it's an OVERPRICED penny stock because of a PUMP & DUMP operation on it's way back home to PennyLand.